- Alpha Cognition (ACOG) has announced a C$12.5 million public offering led by Raymond James
- The company intends to use the proceeds to develop and market its flagship formulations against Alzheimer’s and ALS
- The offering is expected to close on or about September 29, 2021
- Alpha Cognition is a clinical-stage biopharmaceutical company developing treatments for underserved neurodegenerative diseases
- Alpha Cognition (ACOG) closed down by 11.39 per cent trading at $1.40 per share
Alpha Cognition (ACOG) has announced a C$12.5 million public offering led by Raymond James.
The company will offer 8,350,000 units priced at $1.50 per unit.
Each unit consists of one Alpha common share and one common share purchase warrant.
Each warrant entitles the holder to acquire one common share for $1.75 for 24 months from the closing of the offering.
The company intends to use the proceeds for working capital, general corporate purposes and for the marketing and clinical development of its flagship formulations:
- Alpha-1062, which is intended as a treatment for Alzheimer’s Disease
- Alpha-0602, which is intended as a treatment for ALS
The offering is pursuant to Alpha’s Canadian base-shelf prospectus dated August 25, 2021. The company will file a prospectus supplement in each province and territory except Quebec.
The offering is expected to close on or about September 29, 2021.
Alpha Cognition is a clinical-stage biopharmaceutical company developing treatments for underserved neurodegenerative diseases.
Alpha Cognition (ACOG) closed down by 11.39 per cent trading at $1.40 per share.
